Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS (MEDICAID)

MS Agents (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-855-684-5250**.

When conditions are met, we will authorize the coverage of MS Agents (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name			
Please specify			
Quantity	Frequency Strengt	th	
Route of Administration	Expected Length of therapy	_	
Patient Information Patient Name:			
Patient ID:			
Patient Group No.:			
Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:		
Physician Fax:	Physician Phone:		
Physician Address:	City, State, Zip:		
Diagnosis:	ICD Code:		_
Please circle the appropriate answ	er for each question.		
. Is the requested drug presc	ribed by or in consultation with a neurologist?	Υ	N
[If no, then no further questi	ons.]		
. Has this plan authorized this previous authorization is on	s medication in the past for this patient (i.e., file under this plan)?	Υ	N
[If no, skip to question 15.]			
. Is the patient having a posit	ive clinical response to the medication?	Υ	Ν
[If no, then no further questi	ons.]		
. Is the renewal for Tysabri?		Υ	Ν

	[If yes, then no further questions.]			
5.	Is the renewal for Aubagio?	Υ	N	1
	[If no, skip to question 7.]			
მ.	Has the patient had a CBC, LFT's, and bilirubin that are within normal limits since starting Aubagio?	Υ	١	1
	Please document lab results and date (or submit labs with request):			
	[No further questions.]			
7.	Is the renewal for Tecfidera?	Υ	N	1
	[If no, skip to question 9.]			
3.	Has the patient had a CBC that was within normal limits since starting Tecfidera?	Y	١	1
	Please document lab result and date (or submit labs with request):			
	[No further questions.]			
9.	Is the renewal for Gilenya?	Υ	N	1
	[If no, skip to question 12]			
10	. Has the patient had a CBC, LFT's, and bilirubin that are within normal limits since starting Gilenya?	Y	١	1
	Please document lab results and date (or submit labs with request):			
	[If no, then no further questions.]			
11	.Has the patient had a normal EKG and ophthalmic examination since starting Gilenya?	Υ	١	1
	Please document date of EKG and eye exam (or submit clinical documentation with request):			
	[No further questions.]			
12	. Is the renewal for Lemtrada?	Υ	N	1

[If no, skip to question 14.]		
13. Has the patient received more than 2 years of treatment with Lemtrada?	Υ	N
If yes, please provide rationale for continued treatment:		
[No further questions]		
14. Is the renewal for mitoxantrone?	Υ	N
[If no, then no further questions.]		
[If yes, skip to question 21.]		
15. Is this a request for mitoxantrone?	Υ	N
[If no, skip to question 25.]		
16. Does the patient have a diagnosis of relapsing-remitting multiple sclerosis (RRMS)?	Y	N
[If no, skip to question 18.]		
17. Has the patient had an inadequate response, intolerable side effects, or has a contraindication to 2 formulary agents, one of which must be a formulary interferon or glatiramer acetate agent? (see formulary for a list of preferred agents)	Υ	N
List medications tried and description of failure:		
[If no, no further questions.]		
[If yes, skip to question 19]		
18. Does the patient have a diagnosis of secondary (chronic) progressive MS (SPMS) or progressive relapsing MS (PRMS)?	Υ	N
[If no, then no further questions]		
19. Will all other multiple sclerosis medications (not including Ampyra) be discontinued before starting mitoxantrone?	Υ	N
[If no, then no further questions.]		
20. Is the patient at least 18 years old?	Υ	N
[If no, then no further questions.]		

21. Has the patient received a cumulative lifetime dose of 140mg/m2?	Υ	Ν
[If yes, then no further questions.]		
22. Has the patient had an ECHOcardiogram (EKG) and a CBC within the past 6 months?	Y	N
[If no, then no further questions.]		
23. Was the LVEF (left ventricular ejection fraction) less than 50%?	Υ	Ν
[If yes, then no further questions.]		
24. Did the CBC show an ANC less than 1500 cells/mm3?	Υ	Ν
[No further questions.]		
25. Does the patient have a diagnosis of relapsing-remitting multiple sclerosis?	Y	N
[If yes, skip to question 27.]		
26. Is this a request for Copaxone, Glatopa, or Extavia for a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis (i.e. persons who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with multiple sclerosis)?	Y	N
[If yes, skip to question 44.]		
[If no, then no further questions.]		
27. Is the request for a formulary injectable agent? (refer to formulary for a list of formulary agents)	Y	N
[If yes, skip to question 44.]		
28. Is the request for a non-formulary injectable agent?	Υ	Ν
[If no, skip to question 35.]		
29. Is the request for Avonex, Betaseron, Plegridy or Zinbryta?	Υ	Ν
[If yes, skip to question 43.]		
30. Is the request for Lemtrada?	Υ	Ν
[If no, skip to question 33.]		
31. Does the patient have HIV infection?	Υ	N

[If	yes, no further questions.]		
	as the patient already received a 2 year course of therapy with emtrada?	Y	N
[If	yes, no further questions.]		
[If	no, skip to question 43.]		
33. ls 1	the request for Tysabri?	Υ	N
[If	no, then no further questions.]		
34. Ha	as an anti-JCV antibody test (ELISA) been completed?	Υ	N
	ote: Those with positive anti-JCV antibody have a higher risk for eveloping progressive multifocal leukoencephalopathy (PML).		
[G	o to question 43.]		
35. ls 1	the request for Aubagio?	Υ	N
[If	no, skip to question 37.]		
Co tes	ave all of the following labs been completed within the last 6 months: A) omplete blood count (CBC) that is within normal limits, B) Liver function sts (LFTs) and bilirubin levels that are within normal limits, C) Negative egnancy test if female, and D) Negative tuberculin skin test for latent TB	Y	N
[If	yes, skip to question 44.]		
[If	no, no further questions.]		
37. ls 1	the request for Gilenya?	Υ	N
[If	no, skip to question 41.]		
Co tes pre	ave all of the following labs been completed within the last 6 months: A) omplete blood count (CBC) that is within normal limits, B) Liver function sts (LFTs) and bilirubin levels that are within normal limits, C) Negative egnancy test if female, D) EKG evaluation that is within normal limits, and E) Normal ophthalmic examination	Y	N
[If	no, no further questions.]		
for	pes the patient have a confirmed history of chicken pox OR vaccination the varicella zoster virus OR lab testing confirming varicella tibodies?	Y	N

Prescriber (Or Authorized) Signature	Date	
I affirm that the information given on this form is true and accurate as of this da	ate.	
Comments:		
45. Is the patient at least 18 years old (or 17 years old for Lemtrada)?	Υ	N
[If no, then no further questions]		
44. Will all other multiple sclerosis medications (not including Ampyra) be discontinued before starting the requested medication?	Y	N
[If no, then no further questions.]		
List medications tried and description of failure:		
43. Has the patient had an inadequate response, intolerable side effects, of has a contraindication to 2 formulary agents, one of which must be a formulary interferon or glatiramer acetate agent? (see formulary for a of preferred agents)		N
[If no, no further questions.]		
[If yes, skip to question 44.]		
42. Has the patient had a normal complete blood count within the past 6 months?	Υ	N
[If no, then no further questions.]		
41. Is the request for Tecfidera?	Υ	N
[If no, skip to question 44.]		
[If yes, then no further questions.]		
40. Has the patient experienced any of the following within the last 6 mont A) myocardial infarction, B) unstable angina, C) stroke, or D) TIA (transient ischemic attack)	hs: Y	N
[If no, then no further questions.]		